Calyxo

Calyxo, Inc. is a medical device company focused on improving kidney stone treatment. Founded in February 2016, the company has developed the CVAC Aspiration System, a novel technology that utilizes irrigation and aspiration to remove kidney stones after laser lithotripsy. The goal is to achieve a surgically stone-free outcome, which has traditionally been challenging. The CVAC System enables urologists to safely and effectively remove a significant proportion of stone fragments created during the procedure, minimizing residual stone burden.

Calyxo's innovative approach addresses a pressing need, as kidney stone disease affects approximately 10% of the US population and brings significant healthcare costs, estimated to reach USD 4.1 billion in annual direct treatment costs by 2030. Existing treatments often leave behind residual fragments, leading to a 20%-44% incidence of post-procedural complications such as pain, infection, emergency department visits, hospitalization, and the need for retreatment.

The CVAC Aspiration System has already been used to successfully treat more than 1,500 patients in the US, demonstrating its ability to achieve 97% volumetric stone clearance and a high likelihood of avoiding secondary or more invasive procedures. In March 2024, Calyxo received FDA clearance for a redesigned, next-generation CVAC System, incorporating direct visualization, dedicated irrigation channels, and a large aspiration lumen for enhanced stone clearance. Over 50 procedures have already been performed with the new system, yielding positive patient outcomes and physician feedback.